Burk Jubelt, MD

Current Appointments

• Professor of Neurology
• Professor of Microbiology and Immunology
• Professor of Neuroscience Graduate Program

Hospital Campus

• Downtown

Clinic/Unit

• Multiple Sclerosis Clinic
  University Health Care Center
  Google Maps & Directions
  4th Floor, 90 Presidential Plaza
  Syracuse, NY 13202
  315 464-4243
  
• Post-Polio Syndrome Research and Treatment Center
  University Health Care Center
  Google Maps & Directions
  4th Floor, 90 Presidential Plaza
  Syracuse, NY 13202
  315 464-4243
  
• Neurology Clinic
  University Health Care Center
  Google Maps & Directions
  4th Fl., 90 Presidential Plaza
  Syracuse, NY 13202
  315 464-4243
  

Web Resources

• Professional Site

Education & Fellowships

• Fellowship: Johns Hopkins University School of Medicine, 1979, Virology/Immunology
• Residency: Presbyterian Hospital, Columbia University, 1976
• MD: University of Kansas School of Medicine, 1972

Previous Appointments

• Northwestern University Medical School, 1979–1989

Specialties & Certification

• Neurology

Diseases & Conditions Treated

• Multiple Sclerosis (MS)
• Post Polio Syndrome

Treats

• Adults

Associations/Memberships

• American Academy of Neurology (AAN)
• American Neurological Association

Current Hospital Privileges

• Upstate University Hospital
• Crouse Hospital
• VA Medical Center

Web Resources

• Professional Site

Research Abstract

Post-Polio Syndrome(PPS) in the Mouse.  We have developed a model of PPS in the mouse in order to analyze pathogenesis and try different modalities of treatment.  The growth factors GDNF and IGF1 have resulted in improved strength of the Post-Polio mouse.  

Amyotrophic Lateral Sclerosis (ALS) Motor Neuron Gene Expression. Motor neurons have been isolated from autopsy spinal cords of ALS patients and controls. RNA has been isolated from these motor neurons and cDNA libraries have been constructed. Subtraction of these libraries has begun in an attempt to identify motor neuron specific genes and gene products.

Multiple Sclerosis Treatment.  Mechanisms of action of present MS disease modifying agents.  Development of new disease modifying agents.

References:

1.  Christophi GP, Christophi JA, Gruber RC, Mihai C, Mejico LJ, Jubeltb.  Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-B 1a treated multiple sclerosis patients.  J Nourol Sci 2011; 307: 41-45.

2.  Jubelt B, Mihai C, Li TM, Veerapaneni P. Rhombencephalitis / Brainstem Encephalitia.  Curr Neurol Neurosci Rep 2011; 11:

3. Kister I et al.  Rapid disaese course in African Americans with multiple sclerosis.  Neurology 2010; 75: 217-223.

4.  Jubelt B et al. Retrograde viral delivery of GDNF and IGF1 prevents the development of late weakness (Post-Polio Syndrome) in a mouse model. Neurology 2009 (suppl 3):A362.